Development of ELISA-based methods to measure the anti-malarial drug chloroquine in plasma and in pharmaceutical formulations

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Development of ELISA-based methods to measure the anti-malarial drug chloroquine in plasma and in pharmaceutical formulations. / Khalil, Insaf F; Alifrangis, Michael; Recke, Camilla; Hoegberg, Lotte C; Ronn, Anita; Bygbjerg, Ib C; Koch, Claus.

In: Malaria Journal, Vol. 10, 01.01.2011, p. 249.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Khalil, IF, Alifrangis, M, Recke, C, Hoegberg, LC, Ronn, A, Bygbjerg, IC & Koch, C 2011, 'Development of ELISA-based methods to measure the anti-malarial drug chloroquine in plasma and in pharmaceutical formulations', Malaria Journal, vol. 10, pp. 249. https://doi.org/10.1186/1475-2875-10-249

APA

Khalil, I. F., Alifrangis, M., Recke, C., Hoegberg, L. C., Ronn, A., Bygbjerg, I. C., & Koch, C. (2011). Development of ELISA-based methods to measure the anti-malarial drug chloroquine in plasma and in pharmaceutical formulations. Malaria Journal, 10, 249. https://doi.org/10.1186/1475-2875-10-249

Vancouver

Khalil IF, Alifrangis M, Recke C, Hoegberg LC, Ronn A, Bygbjerg IC et al. Development of ELISA-based methods to measure the anti-malarial drug chloroquine in plasma and in pharmaceutical formulations. Malaria Journal. 2011 Jan 1;10:249. https://doi.org/10.1186/1475-2875-10-249

Author

Khalil, Insaf F ; Alifrangis, Michael ; Recke, Camilla ; Hoegberg, Lotte C ; Ronn, Anita ; Bygbjerg, Ib C ; Koch, Claus. / Development of ELISA-based methods to measure the anti-malarial drug chloroquine in plasma and in pharmaceutical formulations. In: Malaria Journal. 2011 ; Vol. 10. pp. 249.

Bibtex

@article{a205585a1ebb4995a69ab5d4dd36fc3f,
title = "Development of ELISA-based methods to measure the anti-malarial drug chloroquine in plasma and in pharmaceutical formulations",
abstract = "In Central and South America and Eastern and Southern Africa, Plasmodium vivax infections accounts for 71-81% and 5% of malaria cases, respectively. In these areas, chloroquine (CQ) remains the treatment of choice for P. vivax malaria. In addition, CQ has recently proven to be an effective HIV-1 therapeutic agent. There is a dire need to continue monitoring quality of CQ as there is a major influx of substandard and fake formulations into malaria-endemic countries. The use of fake/substandard drugs will result in sub-therapeutic levels endangering the patient and possibly select for parasite resistance. The aim of this study was to develop an inexpensive, simple antibody-based ELISA to measure CQ concentrations in tablets and in plasma.",
author = "Khalil, {Insaf F} and Michael Alifrangis and Camilla Recke and Hoegberg, {Lotte C} and Anita Ronn and Bygbjerg, {Ib C} and Claus Koch",
year = "2011",
month = jan,
day = "1",
doi = "10.1186/1475-2875-10-249",
language = "English",
volume = "10",
pages = "249",
journal = "Malaria Journal",
issn = "1475-2875",
publisher = "BioMed Central",

}

RIS

TY - JOUR

T1 - Development of ELISA-based methods to measure the anti-malarial drug chloroquine in plasma and in pharmaceutical formulations

AU - Khalil, Insaf F

AU - Alifrangis, Michael

AU - Recke, Camilla

AU - Hoegberg, Lotte C

AU - Ronn, Anita

AU - Bygbjerg, Ib C

AU - Koch, Claus

PY - 2011/1/1

Y1 - 2011/1/1

N2 - In Central and South America and Eastern and Southern Africa, Plasmodium vivax infections accounts for 71-81% and 5% of malaria cases, respectively. In these areas, chloroquine (CQ) remains the treatment of choice for P. vivax malaria. In addition, CQ has recently proven to be an effective HIV-1 therapeutic agent. There is a dire need to continue monitoring quality of CQ as there is a major influx of substandard and fake formulations into malaria-endemic countries. The use of fake/substandard drugs will result in sub-therapeutic levels endangering the patient and possibly select for parasite resistance. The aim of this study was to develop an inexpensive, simple antibody-based ELISA to measure CQ concentrations in tablets and in plasma.

AB - In Central and South America and Eastern and Southern Africa, Plasmodium vivax infections accounts for 71-81% and 5% of malaria cases, respectively. In these areas, chloroquine (CQ) remains the treatment of choice for P. vivax malaria. In addition, CQ has recently proven to be an effective HIV-1 therapeutic agent. There is a dire need to continue monitoring quality of CQ as there is a major influx of substandard and fake formulations into malaria-endemic countries. The use of fake/substandard drugs will result in sub-therapeutic levels endangering the patient and possibly select for parasite resistance. The aim of this study was to develop an inexpensive, simple antibody-based ELISA to measure CQ concentrations in tablets and in plasma.

U2 - 10.1186/1475-2875-10-249

DO - 10.1186/1475-2875-10-249

M3 - Journal article

C2 - 21864375

VL - 10

SP - 249

JO - Malaria Journal

JF - Malaria Journal

SN - 1475-2875

ER -

ID: 35277189